Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Net Income towards Common Stockholders (2016 - 2021)

Phio Pharmaceuticals' Net Income towards Common Stockholders history spans 10 years, with the latest figure at -$3.5 million for Q4 2021.

  • For Q4 2021, Net Income towards Common Stockholders fell 40.17% year-over-year to -$3.5 million; the TTM value through Dec 2021 reached -$13.5 million, down 53.74%, while the annual FY2024 figure was -$7.4 million, 31.75% up from the prior year.
  • Net Income towards Common Stockholders reached -$3.5 million in Q4 2021 per PHIO's latest filing, up from -$3.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.5 million in Q3 2018 to a low of -$5.5 million in Q1 2017.
  • Average Net Income towards Common Stockholders over 5 years is -$2.6 million, with a median of -$2.3 million recorded in 2020.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 144.73% in 2017, then skyrocketed 58.99% in 2018.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.0 million in 2017, then grew by 13.74% to -$1.7 million in 2018, then plummeted by 54.55% to -$2.7 million in 2019, then rose by 7.76% to -$2.5 million in 2020, then plummeted by 40.17% to -$3.5 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Net Income towards Common Stockholders are -$3.5 million (Q4 2021), -$3.7 million (Q3 2021), and -$2.7 million (Q2 2021).